nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—migraine—Prednisone—hematologic cancer	0.622	1	CpDpCtD
Naratriptan—Sumatriptan—ABCG2—hematologic cancer	0.000577	0.57	CrCbGaD
Naratriptan—Sumatriptan—ABCB1—hematologic cancer	0.00024	0.237	CrCbGaD
Naratriptan—Eletriptan—ABCB1—hematologic cancer	0.000195	0.192	CrCbGaD
Naratriptan—Bradycardia—Doxorubicin—hematologic cancer	3.31e-05	0.000104	CcSEcCtD
Naratriptan—Paraesthesia—Dexamethasone—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Naratriptan—Paraesthesia—Betamethasone—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Naratriptan—Discomfort—Prednisone—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Naratriptan—Rash—Gemcitabine—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Naratriptan—Dermatitis—Gemcitabine—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Naratriptan—Hypersensitivity—Etoposide—hematologic cancer	3.28e-05	0.000103	CcSEcCtD
Naratriptan—Tinnitus—Epirubicin—hematologic cancer	3.28e-05	0.000103	CcSEcCtD
Naratriptan—Erythema—Methotrexate—hematologic cancer	3.27e-05	0.000103	CcSEcCtD
Naratriptan—Haemoglobin—Doxorubicin—hematologic cancer	3.27e-05	0.000103	CcSEcCtD
Naratriptan—Headache—Gemcitabine—hematologic cancer	3.27e-05	0.000103	CcSEcCtD
Naratriptan—Nausea—Vincristine—hematologic cancer	3.27e-05	0.000103	CcSEcCtD
Naratriptan—Cardiac disorder—Epirubicin—hematologic cancer	3.26e-05	0.000103	CcSEcCtD
Naratriptan—Haemorrhage—Doxorubicin—hematologic cancer	3.25e-05	0.000102	CcSEcCtD
Naratriptan—Hypersensitivity—Prednisolone—hematologic cancer	3.24e-05	0.000102	CcSEcCtD
Naratriptan—Hypoaesthesia—Doxorubicin—hematologic cancer	3.24e-05	0.000102	CcSEcCtD
Naratriptan—Urticaria—Triamcinolone—hematologic cancer	3.21e-05	0.000101	CcSEcCtD
Naratriptan—Asthenia—Etoposide—hematologic cancer	3.2e-05	0.0001	CcSEcCtD
Naratriptan—Body temperature increased—Triamcinolone—hematologic cancer	3.2e-05	0.0001	CcSEcCtD
Naratriptan—Anaphylactic shock—Prednisone—hematologic cancer	3.19e-05	0.0001	CcSEcCtD
Naratriptan—Oedema—Prednisone—hematologic cancer	3.19e-05	0.0001	CcSEcCtD
Naratriptan—Angiopathy—Epirubicin—hematologic cancer	3.19e-05	0.0001	CcSEcCtD
Naratriptan—Nausea—Irinotecan—hematologic cancer	3.18e-05	0.0001	CcSEcCtD
Naratriptan—Nausea—Mitoxantrone—hematologic cancer	3.18e-05	0.0001	CcSEcCtD
Naratriptan—Immune system disorder—Epirubicin—hematologic cancer	3.18e-05	9.98e-05	CcSEcCtD
Naratriptan—Infection—Prednisone—hematologic cancer	3.17e-05	9.97e-05	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.17e-05	9.95e-05	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.17e-05	9.95e-05	CcSEcCtD
Naratriptan—Fatigue—Betamethasone—hematologic cancer	3.16e-05	9.94e-05	CcSEcCtD
Naratriptan—Fatigue—Dexamethasone—hematologic cancer	3.16e-05	9.94e-05	CcSEcCtD
Naratriptan—Chills—Epirubicin—hematologic cancer	3.15e-05	9.91e-05	CcSEcCtD
Naratriptan—Pruritus—Etoposide—hematologic cancer	3.15e-05	9.91e-05	CcSEcCtD
Naratriptan—Shock—Prednisone—hematologic cancer	3.14e-05	9.88e-05	CcSEcCtD
Naratriptan—Arrhythmia—Epirubicin—hematologic cancer	3.14e-05	9.87e-05	CcSEcCtD
Naratriptan—Pain—Betamethasone—hematologic cancer	3.14e-05	9.86e-05	CcSEcCtD
Naratriptan—Pain—Dexamethasone—hematologic cancer	3.14e-05	9.86e-05	CcSEcCtD
Naratriptan—Nervous system disorder—Prednisone—hematologic cancer	3.13e-05	9.84e-05	CcSEcCtD
Naratriptan—Alopecia—Epirubicin—hematologic cancer	3.11e-05	9.76e-05	CcSEcCtD
Naratriptan—Skin disorder—Prednisone—hematologic cancer	3.1e-05	9.75e-05	CcSEcCtD
Naratriptan—Nausea—Gemcitabine—hematologic cancer	3.1e-05	9.74e-05	CcSEcCtD
Naratriptan—Vomiting—Cisplatin—hematologic cancer	3.09e-05	9.72e-05	CcSEcCtD
Naratriptan—Hyperhidrosis—Prednisone—hematologic cancer	3.09e-05	9.7e-05	CcSEcCtD
Naratriptan—Vision blurred—Methotrexate—hematologic cancer	3.08e-05	9.69e-05	CcSEcCtD
Naratriptan—Rash—Cisplatin—hematologic cancer	3.07e-05	9.64e-05	CcSEcCtD
Naratriptan—Dermatitis—Cisplatin—hematologic cancer	3.06e-05	9.63e-05	CcSEcCtD
Naratriptan—Erythema—Epirubicin—hematologic cancer	3.06e-05	9.62e-05	CcSEcCtD
Naratriptan—Diarrhoea—Etoposide—hematologic cancer	3.05e-05	9.58e-05	CcSEcCtD
Naratriptan—Ill-defined disorder—Methotrexate—hematologic cancer	3.03e-05	9.54e-05	CcSEcCtD
Naratriptan—Tinnitus—Doxorubicin—hematologic cancer	3.03e-05	9.53e-05	CcSEcCtD
Naratriptan—Anaemia—Methotrexate—hematologic cancer	3.02e-05	9.5e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Betamethasone—hematologic cancer	3.02e-05	9.5e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Dexamethasone—hematologic cancer	3.02e-05	9.5e-05	CcSEcCtD
Naratriptan—Cardiac disorder—Doxorubicin—hematologic cancer	3.02e-05	9.49e-05	CcSEcCtD
Naratriptan—Hypersensitivity—Triamcinolone—hematologic cancer	2.98e-05	9.36e-05	CcSEcCtD
Naratriptan—Angiopathy—Doxorubicin—hematologic cancer	2.95e-05	9.28e-05	CcSEcCtD
Naratriptan—Malaise—Methotrexate—hematologic cancer	2.95e-05	9.27e-05	CcSEcCtD
Naratriptan—Dizziness—Etoposide—hematologic cancer	2.95e-05	9.26e-05	CcSEcCtD
Naratriptan—Muscle spasms—Epirubicin—hematologic cancer	2.94e-05	9.25e-05	CcSEcCtD
Naratriptan—Immune system disorder—Doxorubicin—hematologic cancer	2.94e-05	9.24e-05	CcSEcCtD
Naratriptan—Vertigo—Methotrexate—hematologic cancer	2.94e-05	9.23e-05	CcSEcCtD
Naratriptan—Chills—Doxorubicin—hematologic cancer	2.92e-05	9.17e-05	CcSEcCtD
Naratriptan—Urticaria—Dexamethasone—hematologic cancer	2.91e-05	9.16e-05	CcSEcCtD
Naratriptan—Urticaria—Betamethasone—hematologic cancer	2.91e-05	9.16e-05	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.91e-05	9.15e-05	CcSEcCtD
Naratriptan—Dizziness—Prednisolone—hematologic cancer	2.91e-05	9.13e-05	CcSEcCtD
Naratriptan—Arrhythmia—Doxorubicin—hematologic cancer	2.91e-05	9.13e-05	CcSEcCtD
Naratriptan—Asthenia—Triamcinolone—hematologic cancer	2.9e-05	9.11e-05	CcSEcCtD
Naratriptan—Body temperature increased—Dexamethasone—hematologic cancer	2.9e-05	9.11e-05	CcSEcCtD
Naratriptan—Body temperature increased—Betamethasone—hematologic cancer	2.9e-05	9.11e-05	CcSEcCtD
Naratriptan—Nausea—Cisplatin—hematologic cancer	2.89e-05	9.08e-05	CcSEcCtD
Naratriptan—Vision blurred—Epirubicin—hematologic cancer	2.88e-05	9.07e-05	CcSEcCtD
Naratriptan—Alopecia—Doxorubicin—hematologic cancer	2.87e-05	9.03e-05	CcSEcCtD
Naratriptan—Paraesthesia—Prednisone—hematologic cancer	2.87e-05	9.01e-05	CcSEcCtD
Naratriptan—Pruritus—Triamcinolone—hematologic cancer	2.86e-05	8.99e-05	CcSEcCtD
Naratriptan—Cough—Methotrexate—hematologic cancer	2.85e-05	8.97e-05	CcSEcCtD
Naratriptan—Ill-defined disorder—Epirubicin—hematologic cancer	2.84e-05	8.93e-05	CcSEcCtD
Naratriptan—Convulsion—Methotrexate—hematologic cancer	2.83e-05	8.91e-05	CcSEcCtD
Naratriptan—Vomiting—Etoposide—hematologic cancer	2.83e-05	8.9e-05	CcSEcCtD
Naratriptan—Erythema—Doxorubicin—hematologic cancer	2.83e-05	8.9e-05	CcSEcCtD
Naratriptan—Anaemia—Epirubicin—hematologic cancer	2.83e-05	8.89e-05	CcSEcCtD
Naratriptan—Agitation—Epirubicin—hematologic cancer	2.81e-05	8.84e-05	CcSEcCtD
Naratriptan—Rash—Etoposide—hematologic cancer	2.81e-05	8.83e-05	CcSEcCtD
Naratriptan—Dermatitis—Etoposide—hematologic cancer	2.81e-05	8.82e-05	CcSEcCtD
Naratriptan—Headache—Etoposide—hematologic cancer	2.79e-05	8.77e-05	CcSEcCtD
Naratriptan—Arthralgia—Methotrexate—hematologic cancer	2.78e-05	8.75e-05	CcSEcCtD
Naratriptan—Myalgia—Methotrexate—hematologic cancer	2.78e-05	8.75e-05	CcSEcCtD
Naratriptan—Rash—Prednisolone—hematologic cancer	2.77e-05	8.71e-05	CcSEcCtD
Naratriptan—Dermatitis—Prednisolone—hematologic cancer	2.77e-05	8.7e-05	CcSEcCtD
Naratriptan—Malaise—Epirubicin—hematologic cancer	2.76e-05	8.67e-05	CcSEcCtD
Naratriptan—Fatigue—Prednisone—hematologic cancer	2.75e-05	8.65e-05	CcSEcCtD
Naratriptan—Headache—Prednisolone—hematologic cancer	2.75e-05	8.65e-05	CcSEcCtD
Naratriptan—Discomfort—Methotrexate—hematologic cancer	2.75e-05	8.65e-05	CcSEcCtD
Naratriptan—Vertigo—Epirubicin—hematologic cancer	2.75e-05	8.64e-05	CcSEcCtD
Naratriptan—Syncope—Epirubicin—hematologic cancer	2.74e-05	8.63e-05	CcSEcCtD
Naratriptan—Constipation—Prednisone—hematologic cancer	2.73e-05	8.58e-05	CcSEcCtD
Naratriptan—Muscle spasms—Doxorubicin—hematologic cancer	2.72e-05	8.56e-05	CcSEcCtD
Naratriptan—Palpitations—Epirubicin—hematologic cancer	2.7e-05	8.5e-05	CcSEcCtD
Naratriptan—Confusional state—Methotrexate—hematologic cancer	2.69e-05	8.46e-05	CcSEcCtD
Naratriptan—Loss of consciousness—Epirubicin—hematologic cancer	2.69e-05	8.45e-05	CcSEcCtD
Naratriptan—Dizziness—Triamcinolone—hematologic cancer	2.67e-05	8.4e-05	CcSEcCtD
Naratriptan—Cough—Epirubicin—hematologic cancer	2.67e-05	8.39e-05	CcSEcCtD
Naratriptan—Anaphylactic shock—Methotrexate—hematologic cancer	2.67e-05	8.39e-05	CcSEcCtD
Naratriptan—Vision blurred—Doxorubicin—hematologic cancer	2.67e-05	8.39e-05	CcSEcCtD
Naratriptan—Convulsion—Epirubicin—hematologic cancer	2.65e-05	8.33e-05	CcSEcCtD
Naratriptan—Infection—Methotrexate—hematologic cancer	2.65e-05	8.33e-05	CcSEcCtD
Naratriptan—Nausea—Etoposide—hematologic cancer	2.65e-05	8.32e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Prednisone—hematologic cancer	2.63e-05	8.27e-05	CcSEcCtD
Naratriptan—Asthenia—Dexamethasone—hematologic cancer	2.63e-05	8.27e-05	CcSEcCtD
Naratriptan—Asthenia—Betamethasone—hematologic cancer	2.63e-05	8.27e-05	CcSEcCtD
Naratriptan—Ill-defined disorder—Doxorubicin—hematologic cancer	2.63e-05	8.26e-05	CcSEcCtD
Naratriptan—Nervous system disorder—Methotrexate—hematologic cancer	2.62e-05	8.23e-05	CcSEcCtD
Naratriptan—Anaemia—Doxorubicin—hematologic cancer	2.62e-05	8.23e-05	CcSEcCtD
Naratriptan—Thrombocytopenia—Methotrexate—hematologic cancer	2.61e-05	8.21e-05	CcSEcCtD
Naratriptan—Nausea—Prednisolone—hematologic cancer	2.61e-05	8.21e-05	CcSEcCtD
Naratriptan—Myalgia—Epirubicin—hematologic cancer	2.61e-05	8.19e-05	CcSEcCtD
Naratriptan—Arthralgia—Epirubicin—hematologic cancer	2.61e-05	8.19e-05	CcSEcCtD
Naratriptan—Agitation—Doxorubicin—hematologic cancer	2.6e-05	8.18e-05	CcSEcCtD
Naratriptan—Anxiety—Epirubicin—hematologic cancer	2.6e-05	8.16e-05	CcSEcCtD
Naratriptan—Pruritus—Betamethasone—hematologic cancer	2.59e-05	8.15e-05	CcSEcCtD
Naratriptan—Pruritus—Dexamethasone—hematologic cancer	2.59e-05	8.15e-05	CcSEcCtD
Naratriptan—Skin disorder—Methotrexate—hematologic cancer	2.59e-05	8.15e-05	CcSEcCtD
Naratriptan—Hyperhidrosis—Methotrexate—hematologic cancer	2.58e-05	8.11e-05	CcSEcCtD
Naratriptan—Discomfort—Epirubicin—hematologic cancer	2.57e-05	8.09e-05	CcSEcCtD
Naratriptan—Vomiting—Triamcinolone—hematologic cancer	2.57e-05	8.08e-05	CcSEcCtD
Naratriptan—Malaise—Doxorubicin—hematologic cancer	2.55e-05	8.03e-05	CcSEcCtD
Naratriptan—Rash—Triamcinolone—hematologic cancer	2.55e-05	8.01e-05	CcSEcCtD
Naratriptan—Dry mouth—Epirubicin—hematologic cancer	2.55e-05	8.01e-05	CcSEcCtD
Naratriptan—Dermatitis—Triamcinolone—hematologic cancer	2.55e-05	8e-05	CcSEcCtD
Naratriptan—Vertigo—Doxorubicin—hematologic cancer	2.54e-05	8e-05	CcSEcCtD
Naratriptan—Syncope—Doxorubicin—hematologic cancer	2.54e-05	7.98e-05	CcSEcCtD
Naratriptan—Urticaria—Prednisone—hematologic cancer	2.54e-05	7.97e-05	CcSEcCtD
Naratriptan—Headache—Triamcinolone—hematologic cancer	2.53e-05	7.96e-05	CcSEcCtD
Naratriptan—Body temperature increased—Prednisone—hematologic cancer	2.52e-05	7.94e-05	CcSEcCtD
Naratriptan—Confusional state—Epirubicin—hematologic cancer	2.52e-05	7.92e-05	CcSEcCtD
Naratriptan—Diarrhoea—Betamethasone—hematologic cancer	2.51e-05	7.89e-05	CcSEcCtD
Naratriptan—Diarrhoea—Dexamethasone—hematologic cancer	2.51e-05	7.89e-05	CcSEcCtD
Naratriptan—Palpitations—Doxorubicin—hematologic cancer	2.5e-05	7.87e-05	CcSEcCtD
Naratriptan—Anaphylactic shock—Epirubicin—hematologic cancer	2.5e-05	7.85e-05	CcSEcCtD
Naratriptan—Oedema—Epirubicin—hematologic cancer	2.5e-05	7.85e-05	CcSEcCtD
Naratriptan—Hypotension—Methotrexate—hematologic cancer	2.49e-05	7.84e-05	CcSEcCtD
Naratriptan—Loss of consciousness—Doxorubicin—hematologic cancer	2.49e-05	7.82e-05	CcSEcCtD
Naratriptan—Infection—Epirubicin—hematologic cancer	2.48e-05	7.8e-05	CcSEcCtD
Naratriptan—Cough—Doxorubicin—hematologic cancer	2.47e-05	7.77e-05	CcSEcCtD
Naratriptan—Shock—Epirubicin—hematologic cancer	2.46e-05	7.72e-05	CcSEcCtD
Naratriptan—Convulsion—Doxorubicin—hematologic cancer	2.45e-05	7.71e-05	CcSEcCtD
Naratriptan—Nervous system disorder—Epirubicin—hematologic cancer	2.45e-05	7.7e-05	CcSEcCtD
Naratriptan—Thrombocytopenia—Epirubicin—hematologic cancer	2.45e-05	7.69e-05	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.43e-05	7.64e-05	CcSEcCtD
Naratriptan—Skin disorder—Epirubicin—hematologic cancer	2.43e-05	7.63e-05	CcSEcCtD
Naratriptan—Dizziness—Dexamethasone—hematologic cancer	2.43e-05	7.62e-05	CcSEcCtD
Naratriptan—Dizziness—Betamethasone—hematologic cancer	2.43e-05	7.62e-05	CcSEcCtD
Naratriptan—Hyperhidrosis—Epirubicin—hematologic cancer	2.41e-05	7.59e-05	CcSEcCtD
Naratriptan—Myalgia—Doxorubicin—hematologic cancer	2.41e-05	7.58e-05	CcSEcCtD
Naratriptan—Arthralgia—Doxorubicin—hematologic cancer	2.41e-05	7.58e-05	CcSEcCtD
Naratriptan—Anxiety—Doxorubicin—hematologic cancer	2.4e-05	7.55e-05	CcSEcCtD
Naratriptan—Nausea—Triamcinolone—hematologic cancer	2.4e-05	7.55e-05	CcSEcCtD
Naratriptan—Paraesthesia—Methotrexate—hematologic cancer	2.4e-05	7.53e-05	CcSEcCtD
Naratriptan—Discomfort—Doxorubicin—hematologic cancer	2.38e-05	7.49e-05	CcSEcCtD
Naratriptan—Dyspnoea—Methotrexate—hematologic cancer	2.38e-05	7.48e-05	CcSEcCtD
Naratriptan—Somnolence—Methotrexate—hematologic cancer	2.37e-05	7.46e-05	CcSEcCtD
Naratriptan—Dry mouth—Doxorubicin—hematologic cancer	2.36e-05	7.41e-05	CcSEcCtD
Naratriptan—Hypersensitivity—Prednisone—hematologic cancer	2.35e-05	7.4e-05	CcSEcCtD
Naratriptan—Hypotension—Epirubicin—hematologic cancer	2.33e-05	7.34e-05	CcSEcCtD
Naratriptan—Vomiting—Betamethasone—hematologic cancer	2.33e-05	7.33e-05	CcSEcCtD
Naratriptan—Vomiting—Dexamethasone—hematologic cancer	2.33e-05	7.33e-05	CcSEcCtD
Naratriptan—Confusional state—Doxorubicin—hematologic cancer	2.33e-05	7.32e-05	CcSEcCtD
Naratriptan—Rash—Betamethasone—hematologic cancer	2.31e-05	7.27e-05	CcSEcCtD
Naratriptan—Rash—Dexamethasone—hematologic cancer	2.31e-05	7.27e-05	CcSEcCtD
Naratriptan—Anaphylactic shock—Doxorubicin—hematologic cancer	2.31e-05	7.26e-05	CcSEcCtD
Naratriptan—Oedema—Doxorubicin—hematologic cancer	2.31e-05	7.26e-05	CcSEcCtD
Naratriptan—Dermatitis—Betamethasone—hematologic cancer	2.31e-05	7.26e-05	CcSEcCtD
Naratriptan—Dermatitis—Dexamethasone—hematologic cancer	2.31e-05	7.26e-05	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.3e-05	7.24e-05	CcSEcCtD
Naratriptan—Fatigue—Methotrexate—hematologic cancer	2.3e-05	7.23e-05	CcSEcCtD
Naratriptan—Headache—Dexamethasone—hematologic cancer	2.3e-05	7.22e-05	CcSEcCtD
Naratriptan—Headache—Betamethasone—hematologic cancer	2.3e-05	7.22e-05	CcSEcCtD
Naratriptan—Infection—Doxorubicin—hematologic cancer	2.3e-05	7.22e-05	CcSEcCtD
Naratriptan—Asthenia—Prednisone—hematologic cancer	2.29e-05	7.2e-05	CcSEcCtD
Naratriptan—Pain—Methotrexate—hematologic cancer	2.28e-05	7.17e-05	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.28e-05	7.15e-05	CcSEcCtD
Naratriptan—Shock—Doxorubicin—hematologic cancer	2.27e-05	7.15e-05	CcSEcCtD
Naratriptan—Nervous system disorder—Doxorubicin—hematologic cancer	2.27e-05	7.12e-05	CcSEcCtD
Naratriptan—Thrombocytopenia—Doxorubicin—hematologic cancer	2.26e-05	7.11e-05	CcSEcCtD
Naratriptan—Pruritus—Prednisone—hematologic cancer	2.26e-05	7.1e-05	CcSEcCtD
Naratriptan—Skin disorder—Doxorubicin—hematologic cancer	2.24e-05	7.06e-05	CcSEcCtD
Naratriptan—Paraesthesia—Epirubicin—hematologic cancer	2.24e-05	7.05e-05	CcSEcCtD
Naratriptan—Hyperhidrosis—Doxorubicin—hematologic cancer	2.23e-05	7.02e-05	CcSEcCtD
Naratriptan—Dyspnoea—Epirubicin—hematologic cancer	2.23e-05	7e-05	CcSEcCtD
Naratriptan—Somnolence—Epirubicin—hematologic cancer	2.22e-05	6.98e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Methotrexate—hematologic cancer	2.2e-05	6.91e-05	CcSEcCtD
Naratriptan—Diarrhoea—Prednisone—hematologic cancer	2.19e-05	6.87e-05	CcSEcCtD
Naratriptan—Nausea—Betamethasone—hematologic cancer	2.18e-05	6.85e-05	CcSEcCtD
Naratriptan—Nausea—Dexamethasone—hematologic cancer	2.18e-05	6.85e-05	CcSEcCtD
Naratriptan—Hypotension—Doxorubicin—hematologic cancer	2.16e-05	6.79e-05	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.16e-05	6.78e-05	CcSEcCtD
Naratriptan—Fatigue—Epirubicin—hematologic cancer	2.15e-05	6.77e-05	CcSEcCtD
Naratriptan—Constipation—Epirubicin—hematologic cancer	2.14e-05	6.71e-05	CcSEcCtD
Naratriptan—Pain—Epirubicin—hematologic cancer	2.14e-05	6.71e-05	CcSEcCtD
Naratriptan—Urticaria—Methotrexate—hematologic cancer	2.12e-05	6.66e-05	CcSEcCtD
Naratriptan—Dizziness—Prednisone—hematologic cancer	2.11e-05	6.64e-05	CcSEcCtD
Naratriptan—Body temperature increased—Methotrexate—hematologic cancer	2.11e-05	6.63e-05	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.11e-05	6.62e-05	CcSEcCtD
Naratriptan—Paraesthesia—Doxorubicin—hematologic cancer	2.08e-05	6.52e-05	CcSEcCtD
Naratriptan—Dyspnoea—Doxorubicin—hematologic cancer	2.06e-05	6.48e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Epirubicin—hematologic cancer	2.06e-05	6.47e-05	CcSEcCtD
Naratriptan—Somnolence—Doxorubicin—hematologic cancer	2.05e-05	6.46e-05	CcSEcCtD
Naratriptan—Vomiting—Prednisone—hematologic cancer	2.03e-05	6.38e-05	CcSEcCtD
Naratriptan—Rash—Prednisone—hematologic cancer	2.01e-05	6.33e-05	CcSEcCtD
Naratriptan—Dermatitis—Prednisone—hematologic cancer	2.01e-05	6.32e-05	CcSEcCtD
Naratriptan—Headache—Prednisone—hematologic cancer	2e-05	6.29e-05	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2e-05	6.27e-05	CcSEcCtD
Naratriptan—Fatigue—Doxorubicin—hematologic cancer	1.99e-05	6.26e-05	CcSEcCtD
Naratriptan—Urticaria—Epirubicin—hematologic cancer	1.98e-05	6.24e-05	CcSEcCtD
Naratriptan—Pain—Doxorubicin—hematologic cancer	1.98e-05	6.21e-05	CcSEcCtD
Naratriptan—Constipation—Doxorubicin—hematologic cancer	1.98e-05	6.21e-05	CcSEcCtD
Naratriptan—Body temperature increased—Epirubicin—hematologic cancer	1.97e-05	6.21e-05	CcSEcCtD
Naratriptan—Hypersensitivity—Methotrexate—hematologic cancer	1.97e-05	6.18e-05	CcSEcCtD
Naratriptan—Asthenia—Methotrexate—hematologic cancer	1.91e-05	6.02e-05	CcSEcCtD
Naratriptan—Feeling abnormal—Doxorubicin—hematologic cancer	1.9e-05	5.99e-05	CcSEcCtD
Naratriptan—Nausea—Prednisone—hematologic cancer	1.9e-05	5.96e-05	CcSEcCtD
Naratriptan—Pruritus—Methotrexate—hematologic cancer	1.89e-05	5.94e-05	CcSEcCtD
Naratriptan—Hypersensitivity—Epirubicin—hematologic cancer	1.84e-05	5.78e-05	CcSEcCtD
Naratriptan—Urticaria—Doxorubicin—hematologic cancer	1.84e-05	5.77e-05	CcSEcCtD
Naratriptan—Body temperature increased—Doxorubicin—hematologic cancer	1.83e-05	5.74e-05	CcSEcCtD
Naratriptan—Diarrhoea—Methotrexate—hematologic cancer	1.83e-05	5.74e-05	CcSEcCtD
Naratriptan—Asthenia—Epirubicin—hematologic cancer	1.79e-05	5.63e-05	CcSEcCtD
Naratriptan—Pruritus—Epirubicin—hematologic cancer	1.77e-05	5.55e-05	CcSEcCtD
Naratriptan—Dizziness—Methotrexate—hematologic cancer	1.76e-05	5.55e-05	CcSEcCtD
Naratriptan—Diarrhoea—Epirubicin—hematologic cancer	1.71e-05	5.37e-05	CcSEcCtD
Naratriptan—Hypersensitivity—Doxorubicin—hematologic cancer	1.7e-05	5.35e-05	CcSEcCtD
Naratriptan—Vomiting—Methotrexate—hematologic cancer	1.7e-05	5.33e-05	CcSEcCtD
Naratriptan—Rash—Methotrexate—hematologic cancer	1.68e-05	5.29e-05	CcSEcCtD
Naratriptan—Dermatitis—Methotrexate—hematologic cancer	1.68e-05	5.28e-05	CcSEcCtD
Naratriptan—Headache—Methotrexate—hematologic cancer	1.67e-05	5.26e-05	CcSEcCtD
Naratriptan—Asthenia—Doxorubicin—hematologic cancer	1.66e-05	5.21e-05	CcSEcCtD
Naratriptan—Dizziness—Epirubicin—hematologic cancer	1.65e-05	5.19e-05	CcSEcCtD
Naratriptan—Pruritus—Doxorubicin—hematologic cancer	1.64e-05	5.14e-05	CcSEcCtD
Naratriptan—Vomiting—Epirubicin—hematologic cancer	1.59e-05	4.99e-05	CcSEcCtD
Naratriptan—Nausea—Methotrexate—hematologic cancer	1.59e-05	4.98e-05	CcSEcCtD
Naratriptan—Diarrhoea—Doxorubicin—hematologic cancer	1.58e-05	4.97e-05	CcSEcCtD
Naratriptan—Rash—Epirubicin—hematologic cancer	1.57e-05	4.95e-05	CcSEcCtD
Naratriptan—Dermatitis—Epirubicin—hematologic cancer	1.57e-05	4.95e-05	CcSEcCtD
Naratriptan—Headache—Epirubicin—hematologic cancer	1.56e-05	4.92e-05	CcSEcCtD
Naratriptan—Dizziness—Doxorubicin—hematologic cancer	1.53e-05	4.8e-05	CcSEcCtD
Naratriptan—Nausea—Epirubicin—hematologic cancer	1.48e-05	4.66e-05	CcSEcCtD
Naratriptan—Vomiting—Doxorubicin—hematologic cancer	1.47e-05	4.62e-05	CcSEcCtD
Naratriptan—Rash—Doxorubicin—hematologic cancer	1.46e-05	4.58e-05	CcSEcCtD
Naratriptan—Dermatitis—Doxorubicin—hematologic cancer	1.46e-05	4.58e-05	CcSEcCtD
Naratriptan—Headache—Doxorubicin—hematologic cancer	1.45e-05	4.55e-05	CcSEcCtD
Naratriptan—Nausea—Doxorubicin—hematologic cancer	1.37e-05	4.31e-05	CcSEcCtD
Naratriptan—HTR1A—Signaling Pathways—HSP90AA1—hematologic cancer	1.08e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SYK—hematologic cancer	1.08e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MDM2—hematologic cancer	1.08e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CD—hematologic cancer	1.07e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CREB1—hematologic cancer	1.05e-05	0.00018	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2RA—hematologic cancer	1.05e-05	0.00018	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CB—hematologic cancer	1.05e-05	0.00018	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MTOR—hematologic cancer	1.05e-05	0.00018	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL2—hematologic cancer	1.04e-05	0.000179	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT1—hematologic cancer	1.04e-05	0.000178	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TERT—hematologic cancer	1.04e-05	0.000178	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL2—hematologic cancer	1.03e-05	0.000176	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2RA—hematologic cancer	1.03e-05	0.000176	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6R—hematologic cancer	1.03e-05	0.000176	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL2—hematologic cancer	1.02e-05	0.000175	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TERT—hematologic cancer	1.02e-05	0.000174	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDGFB—hematologic cancer	1.01e-05	0.000174	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3R1—hematologic cancer	1.01e-05	0.000173	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HRAS—hematologic cancer	1e-05	0.000172	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDGFB—hematologic cancer	9.92e-06	0.00017	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TSC2—hematologic cancer	9.9e-06	0.00017	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1B—hematologic cancer	9.83e-06	0.000169	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—JAK2—hematologic cancer	9.81e-06	0.000168	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAP2K1—hematologic cancer	9.77e-06	0.000168	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—hematologic cancer	9.73e-06	0.000167	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GRB2—hematologic cancer	9.72e-06	0.000167	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CD—hematologic cancer	9.71e-06	0.000167	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFA—hematologic cancer	9.7e-06	0.000166	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TSC2—hematologic cancer	9.7e-06	0.000166	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CASP3—hematologic cancer	9.64e-06	0.000165	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL2—hematologic cancer	9.62e-06	0.000165	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—hematologic cancer	9.57e-06	0.000164	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KITLG—hematologic cancer	9.56e-06	0.000164	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGFR3—hematologic cancer	9.52e-06	0.000163	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK14—hematologic cancer	9.43e-06	0.000162	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCND1—hematologic cancer	9.38e-06	0.000161	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—JUN—hematologic cancer	9.36e-06	0.000161	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT5A—hematologic cancer	9.34e-06	0.00016	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGFR3—hematologic cancer	9.33e-06	0.00016	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CB—hematologic cancer	9.32e-06	0.00016	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN2B—hematologic cancer	9.26e-06	0.000159	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ESR1—hematologic cancer	9.25e-06	0.000159	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK14—hematologic cancer	9.23e-06	0.000158	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CG—hematologic cancer	9.18e-06	0.000157	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3R1—hematologic cancer	9.17e-06	0.000157	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FN1—hematologic cancer	9.14e-06	0.000157	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1A—hematologic cancer	9.07e-06	0.000156	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ESR1—hematologic cancer	9.06e-06	0.000155	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PTEN—hematologic cancer	9.05e-06	0.000155	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—BAD—hematologic cancer	9.03e-06	0.000155	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NFKBIA—hematologic cancer	9.03e-06	0.000155	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CD86—hematologic cancer	8.96e-06	0.000154	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FN1—hematologic cancer	8.95e-06	0.000154	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOTCH1—hematologic cancer	8.94e-06	0.000153	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—JAK2—hematologic cancer	8.91e-06	0.000153	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK8—hematologic cancer	8.86e-06	0.000152	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NFKBIA—hematologic cancer	8.84e-06	0.000152	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—BAD—hematologic cancer	8.84e-06	0.000152	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HES1—hematologic cancer	8.84e-06	0.000152	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—hematologic cancer	8.83e-06	0.000152	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NCOR1—hematologic cancer	8.78e-06	0.000151	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CD80—hematologic cancer	8.76e-06	0.00015	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOTCH1—hematologic cancer	8.76e-06	0.00015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CG—hematologic cancer	8.74e-06	0.00015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KIT—hematologic cancer	8.74e-06	0.00015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—NRAS—hematologic cancer	8.74e-06	0.00015	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF1—hematologic cancer	8.69e-06	0.000149	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CSF2—hematologic cancer	8.69e-06	0.000149	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EP300—hematologic cancer	8.63e-06	0.000148	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTPN11—hematologic cancer	8.59e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CD80—hematologic cancer	8.58e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CG—hematologic cancer	8.56e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KIT—hematologic cancer	8.56e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—NRAS—hematologic cancer	8.56e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FOXO1—hematologic cancer	8.56e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL2—hematologic cancer	8.56e-06	0.000147	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFRB—hematologic cancer	8.55e-06	0.000147	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CREBBP—hematologic cancer	8.51e-06	0.000146	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CB—hematologic cancer	8.46e-06	0.000145	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFRA—hematologic cancer	8.41e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTPN11—hematologic cancer	8.41e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SRC—hematologic cancer	8.4e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JAK1—hematologic cancer	8.38e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCG—hematologic cancer	8.38e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MAPK3—hematologic cancer	8.37e-06	0.000144	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CREB1—hematologic cancer	8.32e-06	0.000143	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—BRAF—hematologic cancer	8.22e-06	0.000141	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MAPK3—hematologic cancer	8.2e-06	0.000141	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—hematologic cancer	8.18e-06	0.00014	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CREB1—hematologic cancer	8.15e-06	0.00014	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL2—hematologic cancer	8.14e-06	0.00014	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6R—hematologic cancer	8.12e-06	0.000139	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CREBBP—hematologic cancer	8.11e-06	0.000139	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STAT3—hematologic cancer	8.1e-06	0.000139	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NRAS—hematologic cancer	8.08e-06	0.000139	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CD—hematologic cancer	8.07e-06	0.000138	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—BRAF—hematologic cancer	8.05e-06	0.000138	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL2—hematologic cancer	7.97e-06	0.000137	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—hematologic cancer	7.96e-06	0.000137	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6R—hematologic cancer	7.95e-06	0.000136	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CREBBP—hematologic cancer	7.94e-06	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2RA—hematologic cancer	7.83e-06	0.000134	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL2—hematologic cancer	7.77e-06	0.000133	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TERT—hematologic cancer	7.74e-06	0.000133	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAP2K1—hematologic cancer	7.74e-06	0.000133	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK3—hematologic cancer	7.74e-06	0.000133	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CD—hematologic cancer	7.69e-06	0.000132	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3R1—hematologic cancer	7.62e-06	0.000131	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CA—hematologic cancer	7.61e-06	0.000131	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAP2K1—hematologic cancer	7.58e-06	0.00013	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFB—hematologic cancer	7.56e-06	0.00013	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CD—hematologic cancer	7.53e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—KRAS—hematologic cancer	7.53e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MYC—hematologic cancer	7.52e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFB1—hematologic cancer	7.51e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CA—hematologic cancer	7.46e-06	0.000128	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TSC2—hematologic cancer	7.39e-06	0.000127	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—KRAS—hematologic cancer	7.37e-06	0.000126	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGF2—hematologic cancer	7.36e-06	0.000126	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3R1—hematologic cancer	7.26e-06	0.000125	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF2—hematologic cancer	7.21e-06	0.000124	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3R1—hematologic cancer	7.11e-06	0.000122	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGFR3—hematologic cancer	7.1e-06	0.000122	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—JAK2—hematologic cancer	7.06e-06	0.000121	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK14—hematologic cancer	7.03e-06	0.000121	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CB—hematologic cancer	7.03e-06	0.000121	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KRAS—hematologic cancer	6.95e-06	0.000119	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CA—hematologic cancer	6.91e-06	0.000119	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—JAK2—hematologic cancer	6.91e-06	0.000119	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ESR1—hematologic cancer	6.9e-06	0.000118	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MDM2—hematologic cancer	6.89e-06	0.000118	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FN1—hematologic cancer	6.82e-06	0.000117	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CA—hematologic cancer	6.77e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MDM2—hematologic cancer	6.74e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—BAD—hematologic cancer	6.73e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NFKBIA—hematologic cancer	6.73e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MTOR—hematologic cancer	6.7e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CB—hematologic cancer	6.7e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOTCH1—hematologic cancer	6.67e-06	0.000114	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MTOR—hematologic cancer	6.56e-06	0.000113	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CB—hematologic cancer	6.56e-06	0.000113	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CD80—hematologic cancer	6.53e-06	0.000112	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CG—hematologic cancer	6.52e-06	0.000112	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KIT—hematologic cancer	6.52e-06	0.000112	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—NRAS—hematologic cancer	6.52e-06	0.000112	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTPN11—hematologic cancer	6.41e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HRAS—hematologic cancer	6.4e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CA—hematologic cancer	6.39e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1B—hematologic cancer	6.29e-06	0.000108	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HRAS—hematologic cancer	6.26e-06	0.000107	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAPK3—hematologic cancer	6.25e-06	0.000107	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—hematologic cancer	6.22e-06	0.000107	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CREB1—hematologic cancer	6.21e-06	0.000107	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—hematologic cancer	6.18e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CASP3—hematologic cancer	6.16e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	6.16e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2—hematologic cancer	6.15e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—BRAF—hematologic cancer	6.13e-06	0.000105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—hematologic cancer	6.12e-06	0.000105	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	6.09e-06	0.000105	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTEN—hematologic cancer	6.08e-06	0.000104	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL2—hematologic cancer	6.07e-06	0.000104	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6R—hematologic cancer	6.06e-06	0.000104	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	6.05e-06	0.000104	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CASP3—hematologic cancer	6.03e-06	0.000104	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2—hematologic cancer	6.03e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCND1—hematologic cancer	6e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—hematologic cancer	6e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—JUN—hematologic cancer	5.99e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HRAS—hematologic cancer	5.91e-06	0.000101	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCND1—hematologic cancer	5.87e-06	0.000101	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—JUN—hematologic cancer	5.86e-06	0.000101	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	5.8e-06	9.96e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—EP300—hematologic cancer	5.79e-06	9.94e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTEN—hematologic cancer	5.79e-06	9.94e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	5.77e-06	9.9e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	5.73e-06	9.84e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	5.68e-06	9.75e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	5.68e-06	9.75e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTEN—hematologic cancer	5.67e-06	9.73e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	5.66e-06	9.72e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—hematologic cancer	5.66e-06	9.71e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	5.65e-06	9.69e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	5.61e-06	9.63e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	5.55e-06	9.52e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	5.53e-06	9.49e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EP300—hematologic cancer	5.52e-06	9.47e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF2—hematologic cancer	5.49e-06	9.42e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	5.41e-06	9.29e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EP300—hematologic cancer	5.41e-06	9.28e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SRC—hematologic cancer	5.37e-06	9.21e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JAK2—hematologic cancer	5.26e-06	9.03e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SRC—hematologic cancer	5.26e-06	9.02e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	5.23e-06	8.97e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—hematologic cancer	5.22e-06	8.95e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT3—hematologic cancer	5.18e-06	8.89e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NRAS—hematologic cancer	5.17e-06	8.86e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	5.16e-06	8.85e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MDM2—hematologic cancer	5.14e-06	8.81e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	5.12e-06	8.79e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT3—hematologic cancer	5.07e-06	8.7e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NRAS—hematologic cancer	5.06e-06	8.68e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MTOR—hematologic cancer	5e-06	8.58e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	5e-06	8.58e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	4.95e-06	8.49e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	4.84e-06	8.31e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MYC—hematologic cancer	4.81e-06	8.26e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	4.8e-06	8.24e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	4.77e-06	8.19e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MYC—hematologic cancer	4.71e-06	8.08e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	4.7e-06	8.06e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	4.69e-06	8.05e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	4.64e-06	7.96e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP3—hematologic cancer	4.6e-06	7.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2—hematologic cancer	4.59e-06	7.88e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—hematologic cancer	4.57e-06	7.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCND1—hematologic cancer	4.47e-06	7.68e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JUN—hematologic cancer	4.47e-06	7.66e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KRAS—hematologic cancer	4.45e-06	7.63e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KRAS—hematologic cancer	4.35e-06	7.47e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	4.33e-06	7.43e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTEN—hematologic cancer	4.32e-06	7.41e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CA—hematologic cancer	4.29e-06	7.36e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	4.22e-06	7.25e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	4.21e-06	7.23e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EP300—hematologic cancer	4.12e-06	7.07e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	4.08e-06	7.01e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SRC—hematologic cancer	4.01e-06	6.87e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	4e-06	6.86e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—hematologic cancer	3.95e-06	6.78e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	3.9e-06	6.69e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—hematologic cancer	3.87e-06	6.64e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT3—hematologic cancer	3.86e-06	6.63e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NRAS—hematologic cancer	3.85e-06	6.61e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HRAS—hematologic cancer	3.78e-06	6.48e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HRAS—hematologic cancer	3.7e-06	6.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	3.69e-06	6.33e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—hematologic cancer	3.62e-06	6.21e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MYC—hematologic cancer	3.59e-06	6.16e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	3.58e-06	6.14e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—hematologic cancer	3.54e-06	6.08e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—hematologic cancer	3.5e-06	6.01e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—hematologic cancer	3.34e-06	5.73e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KRAS—hematologic cancer	3.32e-06	5.69e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—hematologic cancer	3.27e-06	5.61e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	3.05e-06	5.23e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—hematologic cancer	2.95e-06	5.06e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HRAS—hematologic cancer	2.82e-06	4.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—hematologic cancer	2.7e-06	4.63e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—hematologic cancer	2.49e-06	4.27e-05	CbGpPWpGaD
